QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (29) Citing Articles via Google Scholar Google Scholar Articles by Zheng, X. Articles by Zukin, R. S. Search for Related Content PubMed PubMed Citation Articles by Zheng, X. Articles by Zukin, R. S.

 Previous Article  |  Next Article 

Volume 17, Number 22, Issue of November 15, 1997

Ca²⁺ Influx Amplifies Protein Kinase C Potentiation of Recombinant NMDA Receptors

Xin Zheng, Ling Zhang, Alice P. Wang, Michael V. L. Bennett, and R. Suzanne Zukin

Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461

ABSTRACT

INTRODUCTION

MATERIALS AND METHODS

RESULTS

DISCUSSION

FOOTNOTES

REFERENCES

---

ABSTRACT

Protein kinase C (PKC) potentiates NMDA receptors in hippocampal, trigeminal, and spinal neurons. Although PKC phosphorylates the NMDA receptor subunit NR1 at four residues within the C terminal splice cassette C1, the molecular mechanisms underlying PKC potentiation of NMDA responses are not yet known. The present study examined the role of Ca²⁺ in PKC potentiation of recombinant NMDA receptors expressed in Xenopus oocytes. We found that Ca²⁺ influx through PKC-potentiated NMDA receptors can further increase the NMDA response ("Ca²⁺ amplification"). Ca²⁺ amplification required a rise in intracellular Ca²⁺ concentration at or near the intracellular end of the channel and was independent of Ca²⁺-activated Cl current. Ca²⁺ amplification depended on extracellular Ca²⁺ concentration during NMDA application and not during PKC activation. Ca²⁺ amplification was reduced by the membrane-permeant Ca²⁺-chelating agent BAPTA-AM. Mutant receptors with greatly reduced Ca²⁺ permeability did not exhibit Ca²⁺ amplification. Receptors containing the NR1 N-terminal splice cassette showed more Ca²⁺ amplification, possibly because of their larger basal current and therefore greater Ca²⁺ influx. Contrary to expectation, splicing out the two C-terminal splice cassettes of NR1 enhanced PKC potentiation in a manner independent of extracellular Ca²⁺. This observation indicates that PKC potentiation does not require phosphorylation of the C1 cassette of the NR1 subunit. PKC potentiation of NMDA receptors in vivo is likely to be affected by Ca²⁺ amplification of the potentiated signal; the degree of amplification will depend in part on alternative splicing of the NR1 subunit, which is regulated developmentally and in a cell-specific manner.

Key words: protein kinase C; NMDA receptors; alternative RNA splicing; TPA; BAPTA; Xenopus oocyte

---

INTRODUCTION

The NMDA class of glutamate receptors plays a critical role in synaptic plasticity, formation of neuronal circuitry, and excitotoxicity (for review, see Choi and Rothman, 1990; Constantine-Paton, 1990; Bliss and Collingridge, 1993). Protein phosphorylation and dephosphorylation are thought to be important mechanisms of regulation of synaptic activity. The PKC-activating phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) enhances whole-cell currents (Gerber et al., 1989; Aniksztejn et al., 1992; Chen and Huang, 1992) and channel open probability (Chen and Huang, 1992) of NMDA receptors in hippocampal, trigeminal, and spinal neurons. TPA also potentiates NMDA responses in Xenopus oocytes expressing rat brain mRNA (Durand et al., 1992; Kelso et al., 1992; Urushihara et al., 1992) and recombinant NMDA receptors (Durand et al., 1992, 1993; Kutsuwada et al., 1992; Yamazaki et al., 1992; Mori et al., 1993). Agonists of µ opioid receptors (Chen and Huang, 1991), phosphoinositol-coupled metabotropic glutamate receptors (Aniksztejn et al., 1991, 1992; Kelso et al., 1992; Shen et al., 1995), and muscarinic acetylcholine receptors (Markram and Segal, 1990) potentiate neuronal and recombinant NMDA receptors via activation of PKC. PKC phosphorylates specific residues in the C1 splice cassette in the cytoplasmic C terminus of the NMDA receptor subunit NR1 (Tingley et al., 1993). Phosphorylation at these sites may regulate receptor interactions with the cytoskeleton and clustering at the membrane (Ehlers et al., 1995) but may decrease PKC potentiation (Durand et al., 1993; Sigel et al., 1994).

Ca²⁺ modulates NMDA receptor activity by several mechanisms. Ca²⁺ reduces single-channel conductance by binding in the ion channel (Jahr and Stevens, 1993). Ca²⁺ influx reduces open probability without change in single-channel conductance (producing "slow inactivation") (Legendre et al., 1993; Rosenmund et al., 1995). Binding of Ca²⁺-calmodulin to the cytoplasmic C terminus decreases open probability and may contribute to Ca²⁺-dependent inactivation (Ehlers et al., 1996). High extracellular Ca²⁺ was reported to increase responses of recombinant NMDA receptors expressed in Xenopus oocytes (Koltchine et al., 1996).

NMDA receptors are assembled from NR1 and NR2 subunits (for review, see Nakanishi, 1992; Westbrook, 1994; Mori and Mishina, 1995). The NR1 subunit is encoded by a single gene, and alternative RNA splicing gives rise to eight possible splice variants (Sugihara et al., 1992). NR2 subunits are of four types, NR2A-D, encoded by four different genes (Meguro et al., 1992; Monyer et al., 1992). NMDA receptors are likely to be NR1/NR2 heteromeric complexes in the nervous system (Sheng et al., 1994; Behe et al., 1995; Blahos and Wenthold, 1996). Although injection of NR1 subunit mRNA into oocytes leads to formation of functional receptors with different properties dependent on the splice variant (Durand et al., 1993; Zhang et al., 1994; Zukin and Bennett, 1995), oocytes may provide an NR2 subunit. Oocytes provide a necessary subunit for two other heteromeric channels (Buller and White, 1990; Hedin et al., 1996).

In the present study, we analyzed the effect of extracellular Ca²⁺ on PKC potentiation of recombinant NMDA receptors expressed in Xenopus oocytes. PKC potentiation of specific splice variants was greater when measured in 1 mM Ca²⁺ than when measured in 1 mM Ba²⁺. The increase in potentiation observed in extracellular Ca²⁺ required that the Ca²⁺ be present during opening of the NMDA receptor, not during activation of PKC. The findings are consistent with a process of Ca²⁺-dependent amplification in which Ca²⁺ enters through the potentiated NMDA receptor and binds to its inner face or a closely associated molecule to increase channel open time or conductance. Modulation of PKC potentiation of neuronal NMDA receptors by extracellular Ca²⁺ and by alternative splicing could have important roles in synaptic plasticity and in formation of neural circuitry.

---

MATERIALS AND METHODS

Site-directed mutagenesis. Site-directed mutations were made with the oligonucleotide-directed in vitro mutagenesis system, version 2 (Amersham, Arlington Heights, IL) as described (Zheng et al., 1994). In brief, NR1₀₁₁ and NR1₁₀₀ (nomenclature of NR1 splice variants according to Durand et al., 1993) were subcloned into the pBluescript SK() vector and used to transform the Escherichia coli strain DH5FIQ (Life Technologies, Gaithersburg, MD). Single-stranded DNA template was rescued with M13K07 helper phage (Bio-Rad, Hercules, CA). To make the channel mutants NR1₀₁₁(N598R) and NR1₁₀₀(N619R), we engineered a single codon substitution into the cloned NR1₀₁₁ and NR1₁₀₀ cDNAs to generate subunits carrying an arginine in place of asparagine in the second membrane domain M2. The following oligonucleotide was used for introduction of this change into the coding sequence 5-CCTTCCCCAATGCCGGAGCGGAGCAGGACGCC-3. To engineer the channel mutant NR1₁₁₁(N619R), a BsmI-BamHI fragment containing exons 21 and 22 was shuttled from wild-type NR1₁₁₁ into the mutant NR1₁₀₀(N619R) cDNA.

To introduce N1 insert mutations with reduced positive charges in the NR1₁₁₁ receptor, a BsmI-BamHI fragment containing exons 21 and 22 was shuttled from wild-type NR1₁₁₁ into the mutant M1, M2, and M3 (NR1₁₀₀) cDNAs (Zheng et al., 1994). Mutant NR1₁₁₁ receptors were as follows: N1-1 (K192A, K193A, and R194A), N1-2 (R207A, R208A, and K211A), and N1-3 (K192A, K193A, R194A, R207A, R208A, and K211A). Codon substitutions were confirmed by DNA sequencing across mutationally altered and ligation regions with Sequenase version 2.1 (United States Biochemical, Cleveland, OH).

RNA synthesis. NR1₀₁₁ cDNA was a gift from Dr. S. Nakanishi (Kyoto University, Kyoto, Japan); NR1₁₁₁ cDNA was a gift from Dr. V. R. Anantharam (University of Massachusetts, Worcester, MA) and subcloned to pBluescript SK() vector; NR1₁₀₀ cDNA was cloned in this laboratory (Durand et al., 1992). Mutant NR1 receptors were generated as described above. NR2A was a gift from Dr. M. Mishina (Niigata University, Niigata, Japan). To generate templates for transcription, circular plasmid cDNAs were linearized with NotI (wild-type and mutant NR1₀₁₁, NR2A) or BamHI (wild-type and mutant NR1₁₀₀, NR1₁₁₁). Transcription reactions were performed with T7 and T3 polymerase (Ambion MEGAscript transcription kit, 4 hr at 37°C) in the presence of capped analog or a mMessage mMachine transcription kit (2 hr at 37°C).

Electrophysiological experiments in Xenopus oocytes. Adult female Xenopus laevis (Xenopus I, Ann Arbor, MI) were anesthetized by immersion in ice water or 0.15% aminobenzoic acid ethyl ester, and oocytes were isolated and prepared as described (Kushner et al., 1988, 1989). Selected stage V and VI oocytes were injected with in vitro transcribed RNA (~20 ng/cell; for heteromeric receptor expression, NR1 and NR2 were mixed in a ratio of 1:3) and maintained at 18°C in culture buffer (in mM: 103 NaCl, 2.5 KCl, 2 MgCl₂, 2 CaCl₂, and 5 HEPES, pH 7.5). Three to 7 d after injection, oocytes were clamped at 60 mV in Mg²⁺-free Ca²⁺ Ringer's solution (in mM: 116 NaCl, 2.0 KCl, 1.0 CaCl₂, and 10 HEPES, pH 7.2), unless otherwise specified, with a two-electrode voltage-clamp amplifier (Dagan or Axon Instruments). NMDA (300 µM) together with glycine (10 µM) was bath-applied to elicit responses. Current amplitude was measured at the minimum immediately after the initial peak (indicated by arrows in sample records in Figs. 1, and 5). In some experiments, 1.0 mM CaCl₂ was replaced by 1.0 mM BaCl₂ (Ba²⁺ Ringer's solution), or the concentration of CaCl₂ was changed. In experiments involving 5 and 10 mM Ca²⁺ Ringer's solution, 10 and 20 mM Na⁺-gluconate was substituted for equimolar NaCl to maintain constant concentrations of Na⁺ and Cl.

---

Fig. 1. PKC potentiation of NR1 receptor splice variants differs when measured in Ca²⁺ and in Ba²⁺ Ringer's solution. Xenopus oocytes were injected with NR1₀₁₁, NR1₁₁₁, or NR1₁₀₀ RNA, alone or with NR2A RNA for expression of heteromeric receptors. Three to 7 d after RNA injection, NMDA responses were recorded from oocytes at 60 mV membrane potential using two-electrode voltage clamp. Currents were elicited by bath application of NMDA (300 µM with 10 µM glycine); arrowheads indicate the points of measurement of response amplitude. A, Whole-cell currents recorded before (left) and after (right) 10 min incubation with 100 nM TPA in Ca²⁺ Ringer's solution (top records) or Ba²⁺ Ringer's solution (bottom records). In Ca²⁺ Ringer's solution, splicing in the N1 cassette and splicing out the C1 and C2 cassettes increased the degree of PKC potentiation. In Ba²⁺ Ringer's solution, splicing out the C1 and C2 cassettes increased PKC potentiation, but the N1 cassette had little or no effect. In Ba²⁺ Ringer's solution, current amplitudes of all three splice variants lacked the initial peak current and late, slow rising phase observed in some records in Ca²⁺ Ringer's solution. Each pair of records (before and after TPA) is from a different oocyte. Arrowheads indicate levels at which currents were measured. Current calibration is 100 nA for NR1₀₁₁ responses recorded in Ca²⁺ and in Ba²⁺ and for NR1₁₁₁ responses recorded in Ba²⁺; calibration is 200 nA for all other responses. B, PKC potentiation of NR1₀₁₁, NR1₁₁₁, and NR1₁₀₀ receptors in Ca²⁺ Ringer's solution and Ba²⁺ Ringer's solution. Potentiation was measured as the ratio of the NMDA-induced current (minimum current amplitude after the initial peak response) after TPA application (I_TPA) to the control current before TPA application (I_control). In Ca²⁺ Ringer's solution, TPA potentiated NMDA responses of NR1₀₁₁, NR1₁₁₁, and NR1₁₀₀ receptors to 3.1 ± 0.2-, 6.2 ± 0.4-, and 12.2 ± 0.8-fold of control responses, respectively (open bars). In Ba²⁺ Ringer's solution, TPA potentiated responses of NR1₀₁₁, NR1₁₁₁, and NR1₁₀₀ receptors to 2.3 ± 0.3-, 2.8 ± 0.3-, and 5.7 ± 0.4-fold of control responses, respectively (filled bars). The degree of potentiation of NR1₀₁₁ receptors observed in Ca²⁺ Ringer's solution was slightly greater than that observed in Ba²⁺ Ringer's solution (p < 0.05). In Ca²⁺, but not in Ba²⁺, PKC potentiation of NR1₁₁₁ receptors was significantly greater than that of NR1₀₁₁ receptors (p < 0.001; p > 0.05). For both NR1₁₁₁ and NR1₁₀₀ receptors, the degree of PKC potentiation in Ba²⁺ Ringer's solution was significantly less than in Ca²⁺ Ringer's solution (p < 0.001). In both Ca²⁺ and Ba²⁺, PKC potentiation of NR1₁₀₀ receptors was significantly greater than that of NR1₁₁₁ in the same solution (p < 0.001). In this and the following figures, data represent mean ± SEM; the numbers of experiments are indicated above each bar. C, PKC potentiation of heteromeric NR1₀₁₁/NR2A, NR1₁₁₁/NR2A, and NR1₁₀₀/NR2A receptors in Ca²⁺ Ringer's solution and Ba²⁺ Ringer's solution. Measured as in B. In 1 mM Ca²⁺ Ringer's solution, TPA potentiated NMDA responses of heteromeric NR1₀₁₁/NR2A, NR1₁₁₁/NR2A, and NR1₁₀₀/NR2A receptors to 3.6 ± 0.5-fold (n = 4), 8.2 ± 0.3-fold (n = 4), and 13.7 ± 1.8-fold (n = 4) of control NMDA responses, respectively (open bars). In 1 mM Ba²⁺ Ringer's solution, TPA potentiated NMDA responses of NR1₀₁₁/NR2A, NR1₁₁₁/NR2A, and NR1₁₀₀/NR2A receptors to 3.6 ± 0.4-fold (n = 4), 4.7 ± 0.6-fold (n = 5), and 7.0 ± 0.7-fold (n = 5) of the control responses, respectively (filled bars).
[View Larger Version of this Image (20K GIF file)]

---

---

Fig. 5. Intracellular BAPTA eliminates Ca²⁺ amplification. Xenopus oocytes from the same batch were injected with NR1₁₀₀ RNA. NMDA (300 µM with 10 µM glycine) was applied in Ca²⁺ or Ba²⁺ Ringer's solution. A, In this oocyte, NMDA-induced currents were potentiated to 12.5-fold of control when measured in Ca²⁺ Ringer's solution and 6.8-fold of control when measured in Ba²⁺ Ringer's solution. The potentiated response in Ca²⁺ showed a late, slowly rising phase (see Discussion). The point at which response amplitude was measured for calculation of potentiation is indicated by an arrowhead. B, A different oocyte was incubated in 0.25 mM BAPTA-AM for 20 min after NMDA applications in Ca²⁺ and in Ba²⁺ Ringer's solution. Responses in Ca²⁺ and in Ba²⁺ Ringer's solution were little affected by BAPTA-AM application. Subsequent application of TPA (in Ca²⁺ Ringer's solution) potentiated the responses to 6.4-fold in Ba²⁺ and 7.8-fold in Ca²⁺; i.e., BAPTA had little effect on PKC potentiation measured in Ba²⁺ but reduced the potentiation measured in Ca²⁺ to near the level measured in Ba²⁺. C, A third oocyte was incubated in 0.25 mM BAPTA-AM for 20 min after 10 min in 100 nM TPA. PKC potentiation measured in Ca²⁺ Ringer's solution was reduced to 5.5-fold of control, similar to that measured in Ba²⁺ Ringer's solution (5.7-fold of control). D, Oocytes from a single batch were tested with NMDA in Ca²⁺ and in Ba²⁺ and then treated with TPA or with BAPTA followed by TPA and again tested with NMDA in Ca²⁺ and in Ba²⁺ as in A and B, respectively. PKC potentiation measured in Ca²⁺ was lower in oocytes treated with BAPTA than in controls (p < 0.001, ANOVA) and slightly but not significantly lower than in controls measured in Ba²⁺. Potentiation measured in Ba²⁺ was lower in oocytes treated with BAPTA than in controls, but not significantly so (p > 0.05). Potentiation of BAPTA-treated oocytes measured in Ca²⁺ and in Ba²⁺ was not significantly different (p > 0.05).
[View Larger Version of this Image (22K GIF file)]

---

TPA (1 mM in 10% DMSO) was dissolved in either Ca²⁺ or Ba²⁺ Ringer's solution at a final concentration of 100 nM and bath-applied to oocytes for 10 min, which achieves near-maximal PKC potentiation. The TPA solution was washed out before NMDA application. Acetoxymethyl ester of bis-(o-aminophenoxy)-ethane-N,N,N,N,-tetraacetic acid (BAPTA-AM; 50 mM stock solution in DMSO) was diluted to 0.25 mM in Ca²⁺ Ringer's solution immediately before each experiment. Niflumic acid in 0.5 M stock solution in ethanol was diluted to 0.5 mM in Ca²⁺ Ringer's solution immediately before each experiment. The extent of PKC potentiation varied from batch to batch of oocytes. Therefore, comparisons are within single batches of oocytes or between batches with the same degree of potentiation of a given receptor subtype. Data represent mean ± SEM. Statistical analyses were performed by one-way ANOVA (GraphPad Prism version 3.0).

---

RESULTS

Extracellular Ca²⁺ affects PKC potentiation of recombinant NMDA receptors

To examine the effect of extracellular Ca²⁺ on PKC potentiation of NMDA receptors, we used oocytes expressing recombinant NMDA receptors. We applied NMDA (300 µM with 10 µM glycine) to oocytes clamped at 60 mV in Ba²⁺ or Ca²⁺ Ringer's solution before and after application of TPA. We focused on three NR1 splice variants that differ in their potentiation by PKC: NR1₀₁₁, which is prominent in forebrain and exhibits a relatively low level of potentiation by PKC; NR1₁₁₁, which is also prominent in forebrain and exhibits a moderate level of PKC potentiation; and NR1₁₀₀, which is prominent in midbrain and exhibits a high level of potentiation by PKC (Fig. 1A) (Durand et al., 1993). This choice of splice variants permitted us to evaluate the action of Ca²⁺ on receptors with and without the N-terminal splice cassette N1 by comparison of NR1₀₁₁ and NR1₁₁₁ receptors and on receptors with and without the C-terminal splice cassettes C1 and C2 by comparison of NR1₁₀₀ and NR1₁₁₁ receptors. (When C2 is spliced out, a new unrelated reading frame is opened, which encodes an alternative cassette, C2, of 22 amino acids before a new stop codon is reached.)

In 1 mM Ca²⁺ Ringer's solution, TPA (100 nM) potentiated NMDA responses of NR1₀₁₁-, NR1₁₁₁-, and NR1₁₀₀-injected oocytes to 3.1 ± 0.2-fold (n = 19), 6.2 ± 0.4-fold (n = 21), and 12.2 ± 0.8-fold (n = 16) of control NMDA responses, respectively (Fig. 1A,B). In 1 mM Ba²⁺ Ringer's solution, NMDA responses of all three splice variants lacked the initial peak current observed in the presence of extracellular Ca²⁺ (Fig. 1A, bottom row). In Ba²⁺, TPA potentiated NMDA responses of NR1₀₁₁-, NR1₁₁₁-, and NR1₁₀₀-injected oocytes to 2.3 ± 0.3-fold (n = 8), 2.8 ± 0.3-fold (n = 8), and 5.7 ± 0.4-fold (n = 10) of the control responses, respectively (Fig. 1A,B). Thus, PKC potentiation of the NR1 splice variants containing N1 (NR1₁₁₁ and NR1₁₀₀) was markedly greater in Ca²⁺ than in Ba²⁺, whereas potentiation of the splice variant NR1₀₁₁, which lacks N1, was only slightly greater in Ca²⁺ than in Ba²⁺ Ringer's solution.

We show below that the greater PKC potentiation recorded in Ca²⁺ requires a rise in Ca²⁺ at the intracellular opening of the channel during responses to NMDA after activation of PKC by TPA; we term this effect "Ca²⁺ amplification." The magnitude of the Ca²⁺ amplification is determined by comparison with potentiation measured in Ba²⁺, which we assume to have no amplifying action. Because potentiation is measured as the ratio of responses measured in the same Ringer's solution after and before TPA application, differences in single-channel conductances in Ca²⁺ and Ba²⁺ Ringer's solution should not be a factor, except insofar as PKC potentiation may change channel permeability.

In Ba²⁺ Ringer's solution, potentiation of NR1₀₁₁ receptors was virtually identical to that of NR1₁₁₁ receptors and about half of that of NR1₁₀₀ receptors (Fig. 1A,B). Thus, PKC potentiation in Ba²⁺ is little affected by the N1 cassette but is greater for the NR1 splice variants lacking the C-terminal splice cassettes C1 and C2 (see Durand et al., 1993).

Native NMDA receptors are likely to be heteromeric receptors containing both NR1 and NR2 subunits (Sheng et al., 1994; Behe et al., 1995; Blahos and Wenthold, 1996). To determine whether (1) alternative splicing of NR1 affects PKC potentiation of heteromeric receptors, and (2) there is Ca²⁺ amplification of their responses, similar experiments were performed on oocytes expressing NR2A and one of the three NR1 subunits, NR1₀₁₁, NR1₁₁₁, and NR1₁₀₀. In 1 mM Ca²⁺ Ringer's solution, TPA potentiated NMDA responses of heteromeric NR1₀₁₁/NR2A, NR1₁₁₁/NR2A, and NR1₁₀₀/NR2A receptors to 3.6 ± 0.5-fold (n = 4), 8.2 ± 0.3-fold (n = 4), and 13.7 ± 1.8-fold (n = 4) of control NMDA responses, respectively (Fig. 1C, open bars). In Ba²⁺ Ringer's solution, TPA potentiated NMDA responses of NR1₀₁₁/NR2A, NR1₁₁₁/NR2A, and NR1₁₀₀/NR2A receptors to 3.6 ± 0.4-fold (n = 4), 4.7 ± 0.6-fold (n = 5), and 7.0 ± 0.7-fold (n = 5) of the control responses, respectively (Fig. 1C, filled bars). These findings indicate that PKC potentiation of heteromeric NR1/NR2A receptors is affected by alternative splicing and exhibits Ca²⁺ amplification of the potentiated responses.

The dependence of PKC potentiation on the extracellular Ca²⁺ concentration was investigated over the range of 0.1-10 mM extracellular Ca²⁺ (Fig. 2). At higher extracellular Ca²⁺ concentrations (5-10 mM), the control currents of each of the NR1 splice variants (but not necessarily Ca²⁺ flux through the channel) were reduced compared with those observed at 0.1 mM Ca²⁺ (Fig. 2A; also see Jahr and Stevens, 1993). However, PKC potentiation was markedly increased for both receptors (Fig. 2). Much of the increase in potentiation of NR1₀₁₁ was a result of decrease in control responses rather than increase in the potentiated responses; however, if single-channel conductance was unaffected by potentiation, open probability must have been increased at elevated Ca²⁺. PKC-induced potentiation of NR1₁₀₀ responses was decreased at 10 mM Ca²⁺, relative to that at 5 mM Ca²⁺; the reduction may reflect greater Ca²⁺-induced inactivation. These findings suggest that Ca²⁺ amplification of PKC potentiation increases with Ca²⁺ concentration over a considerable range. Because potentiation of NR1₀₁₁ is increased by increasing external Ca²⁺, both N1 containing and N1 lacking splice variants may share a common mechanism of Ca²⁺ amplification.

---

Fig. 2. The degree of PKC potentiation varies with extracellular Ca²⁺ concentration. A, Responses of NR1₀₁₁ and NR1₁₀₀ receptors were elicited by bath application of NMDA (300 µM with 10 µM glycine) before (left) and after (right) incubation with TPA; responses were measured at indicated concentrations of extracellular Ca²⁺. Each pair of records is from a different oocyte. At 5 and 10 mM Ca²⁺, NaCl was decreased to maintain Cl concentration (see Materials and Methods). PKC potentiation of both receptors increased with extracellular Ca²⁺ concentration in the range of 0.1-5 mM. Control responses (recorded before treatment with TPA) decreased in amplitude with extracellular Ca²⁺. Current calibration is 100 nA for NR1₀₁₁, 200 nA for NR1₁₀₀ in 0.1 and 10 mM Ca²⁺, and 500 nA for other NR1₁₀₀ records. B, PKC potentiation of NR1₀₁₁ and NR1₁₀₀ receptors as a function of extracellular Ca²⁺ concentration. Data represent mean ± SEM of responses of at least three oocytes for each point.
[View Larger Version of this Image (19K GIF file)]

---

Ca²⁺ amplification is not a result of Ca²⁺-activated Cl currents

Xenopus oocytes express endogenous chloride channels that are activated by cytoplasmic free Ca²⁺ [to generate I_Cl(Ca)]. We used the Cl channel blocker niflumic acid to test for possible contamination of the Ca²⁺ amplification of NMDA evoked responses by I_Cl(Ca). In Figure 3A niflumic acid at 0.5 mM, a concentration that largely blocks I_Cl(Ca) evoked by Ca²⁺ entry mediated by ionophore or through voltage-dependent Ca²⁺ channels (Leonard and Kelso, 1990; White and Aylwin, 1990), blocked 17% of the peak (measured to baseline) and 15% of the steady-state NMDA evoked currents in oocytes expressing NR1₁₀₀/NR2A receptors at 1 mM external Ca²⁺ and 60 mV holding potential (first pair of records). Niflumic acid acted rapidly, and we saw no difference between its action whether or not it was applied 20 sec before NMDA plus niflumic acid; the action was also rapidly reversible (see White and Aylwin, 1990). After application of TPA, the same concentration of niflumic acid blocked 21% of the peak and 8% of the plateau phase of the potentiated NMDA responses (second pair of records). In another batch of oocytes, PKC potentiation was to 7.7 ± 0.4-fold (n = 3) and 8.2 ± 0.5-fold (n = 3) of control in the absence and presence of niflumic acid, respectively (p > 0.05), indicating a negligible contribution of I_Cl(Ca) to the measured PKC potentiation. The persistence of an initial peak in niflumic acid suggests that there is a contribution of receptor desensitization to this peak.

---

Fig. 3. Ca²⁺ amplification is not Ca²⁺ activated Cl current. A, The chloride channel blocker niflumic acid has little effect on PKC potentiation measured in Ca²⁺. In an oocyte expressing NR1₁₀₀/NR2A receptors, niflumic acid (0.5 mM) reduced the peak of the NMDA response by 17% and the plateau by 15% before TPA application (first pair of records, 300 µM NMDA with 10 µM glycine). After TPA application, niflumic acid reduced the peak by 21% and the plateau by 8% (second pair of records). Potentiation with and without niflumic acid was 8.2 ± 0.5 (n = 3) and 7.7 ± 0.4 (n = 3), respectively. Lower gain after 10 min TPA application. B, E_Cl is near 20 mV. At 12 mV the NMDA response was triphasic, the first inward phase representing current through NMDA receptors, the second outward phase resulting from superposition of I_Cl(Ca), and the third again being primarily NMDA current. An initial NMDA peak clearly seen at 12 and 18 mV is not separable from I_Cl(Ca) at more negative potentials. C, D, Ca²⁺ amplification persists near E_Cl. C, Sample records showing NMDA elicited responses before and after PKC potentiation at 20 and 60 mV of NR1₀₁₁, NR1₁₁₁, and NR1₁₀₀ receptors. The plateau phase of the responses was reduced at 20 mV; the initial peak was reduced to a greater extent. Current calibrations are in the order of the pairs of records. D, PKC potentiation from records like those in C. Potentiation of NR1₀₁₁ receptors was essentially the same at 20 and 60 mV, indicating that there was no contribution from I_Cl(Ca). For both NR1₁₁₁ and NR1₁₀₀ receptors, PKC potentiation measured at 20 mV was smaller than that measured at 60 mV (p < 0.05 for NR1₁₁₁; p < 0.1 for NR1₁₀₀ receptors). The reduction in potentiation may have been a result of decrease in the driving force for Ca²⁺. At 20 mV potentiation of NR1₁₁₁ receptors was greater than that of NR1₀₁₁ receptors (p < 0.005); potentiation of the two receptors was virtually identical in Ba²⁺ (Fig. 1C). Thus, even at 20 mV, PKC potentiation of the NR1₁₁₁ receptor shows Ca²⁺ amplification.
[View Larger Version of this Image (28K GIF file)]

---

We also tested for a contribution of I_Cl(Ca) by measuring PKC potentiation near the Cl reversal potential, E_Cl. E_Cl is approximately 20 mV in the oocytes, as shown by reversal of a component of the early peak at this potential (Fig. 3B). At 12 mV, the NMDA response has three phases, an inward current through the NMDA receptors, a somewhat delayed outward current ascribable to I_Cl(Ca), and a later plateau current that is again through the NMDA receptors. The data in Figure 3A indicate that the plateau phase has little I_Cl(Ca) component. At 18 mV, the same components are seen, but the net current at the time of the peak in I_Cl(Ca) is inward. At potentials of 20 mV or more negative, the initial NMDA and I_Cl(Ca) peaks are not distinguishable in these records. The presence near E_Cl of an initial NMDA peak greater than the plateau indicates that desensitization contributes to the peak at more negative voltages, as is also indicated by the persistence of the peak in niflumic acid (Fig. 3A). We compared the PKC potentiation observed at 20 and 60 mV of NMDA splice variants that do and do not show Ca²⁺ amplification in 1 mM Ca²⁺. In responses of oocytes expressing NR1₀₁₁, which do not show Ca²⁺ amplification, the degree of potentiation at 20 mV did not differ significantly from that at 60 mV (2.9 ± 0.3 at 20 mV versus 3.1 ± 0.7 at 60 mV), indicating that I_Cl(Ca) does not contribute significantly to PKC potentiation of these receptors (Fig. 3C,D). Responses of oocytes expressing NR1₁₁₁ and NR1₁₀₀ exhibited some reduction (35-45%) in PKC potentiation at 20 mV compared with 60 mV (p < 0.05 for NR1₁₁₁; p < 0.01 for NR1₁₀₀), which is consistent with reduced Ca²⁺ influx attributable to the reduced driving force at the more depolarized potential. PKC potentiation of NR1₁₁₁ receptors did remain greater than that of NR1₀₁₁ receptors (p < 0.005), although potentiation of the two receptors was essentially the same in Ba²⁺ (Fig. 1B). Because Ca²⁺ amplification was not abolished at 20 mV, we conclude that it is not a result of Ca²⁺-activated Cl current. Although splicing in the C1 and C2 cassettes reduced potentiation in Ba²⁺ at 60 mV, this effect was not present at 20 mV.

Ca²⁺ amplification requires extracellular Ca²⁺ during opening of the NMDA channel, not during TPA application

To determine whether extracellular Ca²⁺ acts during TPA application and/or in a subsequent step (e.g., opening of the NMDA channel), we substituted 1 mM Ba²⁺ for 1 mM Ca²⁺ during (1) TPA application; (2) both TPA and NMDA application; and (3) NMDA application only. For the oocytes illustrated in Figure 4, A and B, application of TPA in Ba²⁺ Ringer's solution potentiated the NMDA response measured in Ca²⁺ Ringer's solution (Fig. 4B) to a level similar to that observed when TPA was applied in Ca²⁺ Ringer's solution (Fig. 4A; to 7.7 and 8.3 times control, respectively). In Figure 4, C and D, application of TPA in Ba²⁺ Ringer's solution potentiated the NMDA response measured in Ba²⁺ (Fig. 4C) to a level similar to that observed when TPA was applied in Ca²⁺ Ringer's solution (Fig. 4D; to 5.2 and 4.3 times control, respectively) In Figure 4E, control responses were obtained in Ca²⁺ and in Ba²⁺ Ringer's solution; then TPA was applied in Ba²⁺, and a test response was obtained. Next the oocyte was transferred to Ca²⁺ Ringer's solution, and a test response was obtained within 20 sec. The degree of potentiation measured in Ca²⁺ was greater than that for Ba²⁺ (14- vs 6-fold) and as great as it would have been if the entire experiment had been performed in Ca²⁺. These findings indicate that the Ca²⁺ amplification requires Ca²⁺ during the response to NMDA rather than during the action of TPA.

---

Fig. 4. Ca²⁺ amplification requires extracellular Ca²⁺ during NMDA application, not during PKC activation by TPA. Xenopus oocytes were injected with RNA encoding NR1₁₀₀ (the NR1 splice variant that exhibits the greatest potentiation by PKC). A different oocyte was used to generate each panel of this figure. Currents were elicited by bath application of NMDA (300 µM with 10 µM glycine) in 1 mM Ca²⁺ Ringer's solution (A), 1 mM Ba²⁺ Ringer's solution (C) or the two alternately (B, D, E) before and after 10 min treatment with 100 nM TPA in either Ca²⁺ or Ba²⁺ Ringer's solution. The open and filled bars above the records indicate Ca²⁺ and Ba²⁺ Ringer's solution, respectively. Calibrations are the same for A-E. A, B, The presence of Ca²⁺ during incubation with TPA did not affect potentiation of NMDA responses measured in Ca²⁺. Application of TPA in Ca²⁺ Ringer's solution potentiated the NMDA response measured in Ca²⁺ Ringer's solution to 8.3-fold of the control response measured in Ca²⁺ Ringer's solution. Application of TPA in Ba²⁺ Ringer's solution potentiated the response measured in Ca²⁺ to 7.7-fold of the control response measured in Ca²⁺ Ringer's solution. C, D, The presence of Ca²⁺ during TPA incubation had little effect on potentiation of NMDA responses measured in Ba²⁺ Ringer's solution. Treatment of a representative oocyte with TPA in Ba²⁺ Ringer's solution potentiated the NMDA response measured in Ba²⁺ to 5.2-fold of the control response measured in Ba²⁺; treatment with TPA in Ca²⁺ Ringer's solution potentiated the NMDA response measured in Ba²⁺ by 4.3-fold. Similar results were obtained in three independent experiments involving different batches of oocytes. E, NMDA responses from a single oocyte recorded in Ca²⁺ and Ba²⁺ Ringer's solution before (left records) and after (right records) application of TPA in Ba²⁺ Ringer's solution. The potentiation measured as the ratio of the responses in Ca²⁺ Ringer's solution (14-fold) was greater than that for the responses in Ba²⁺ Ringer's solution (6-fold) and was similar to that observed when the entire sequence was performed in Ca²⁺ Ringer's solution. F, NMDA responses of an oocyte expressing NR1₁₀₀ receptors recorded in 1 mM Ba²⁺, then 1 mM Ca²⁺, then 1 mM Ba²⁺ again, after application of TPA in 1 mM Ba²⁺. On changing from Ba²⁺ to Ca²⁺ Ringer's solution, the response rose immediately from the response in Ba²⁺ to a peak and then fell to a plateau; the time course and amplitude of the response in Ca²⁺ was similar to that observed when NMDA was applied in Ca²⁺ without previous application in Ba²⁺. On transfer to Ba²⁺ solution, the NMDA response immediately decayed to near the level of the potentiated response observed in Ba²⁺.
[View Larger Version of this Image (23K GIF file)]

---

To examine the time course of onset and reversal of Ca²⁺ amplification, we first treated an oocyte expressing NR1₁₀₀ receptors with TPA in 1 mM Ba²⁺ Ringer's solution. We then applied NMDA in 1 mM Ba²⁺, changed the solution to NMDA in 1 mM Ca²⁺, and then returned to NMDA in Ba²⁺ (Fig. 4F). Transfer of the oocyte from Ba²⁺ to Ca²⁺ resulted in a rapid rise to the potentiation level observed in Ca²⁺; the response was characterized by a peak, followed by a decay to a plateau value. Transfer of the oocyte from Ca²⁺ to Ba²⁺ resulted in a rapid return to near the potentiated level in Ba²⁺. These findings suggest that Ca²⁺ amplifies the NMDA response, and that onset and decay of the Ca²⁺ amplification are too rapid to be resolved within the limitations of perfusion in the oocyte system.

Ca²⁺ amplification requires a rise in intracellular free Ca²⁺

To test whether a rise in intracellular Ca²⁺ is required for Ca²⁺ amplification of NMDA responses, we measured TPA potentiation with and without pretreatment of oocytes with the membrane-permeant Ca²⁺ chelator BAPTA-AM. In Figure 5A, PKC potentiation was to 12.5 times control in Ca²⁺ Ringer's solution and to 6.8 times control in Ba²⁺ Ringer's solution. Pretreatment with BAPTA-AM for 20 min had little effect on steady-state currents in Ca²⁺ or in Ba²⁺ (although it did reduce the initial peak in Ca²⁺), but after BAPTA, PKC potentiation of NR1₁₀₀ receptors measured in Ca²⁺ was reduced to 7.8 times control, a value near that obtained in Ba²⁺ (6.4 times control; Fig. 5B). To determine whether BAPTA-AM inhibits activation of PKC by TPA, BAPTA-AM was applied to another oocyte after treatment with TPA (Fig. 5C). Under these conditions, PKC potentiation was similar in Ca²⁺ and in Ba²⁺, i.e., to 5.5 and 5.7 times control, respectively, and was close to that in Ba²⁺ without BAPTA treatment (Fig. 5A). In an additional batch of oocytes expressing NR1₁₀₀, we compared potentiation in controls and after BAPTA treatment, as in Figure 5, A and B. BAPTA treatment reduced potentiation measured in Ca²⁺ to a level not significantly different from that in Ba²⁺ without BAPTA (Fig. 5D). Thus, BAPTA treatment blocks Ca²⁺ amplification. BAPTA also reduced PKC potentiation measured in Ba²⁺ compared with the control potentiation measured in Ba²⁺, but the effect was not significant (p > 0.05). These findings indicate that this degree of BAPTA treatment reduces or blocks Ca²⁺ amplification of the PKC-potentiated response but has little effect on PKC action or on the response measured in Ba²⁺. Longer BAPTA treatment reduced potentiation in Ba²⁺ to a greater extent, which may reflect a requirement for cytoplasmic Ca²⁺ in TPA action.

NMDA receptors with reduced Ca²⁺ permeability do not exhibit the Ca²⁺ amplification

To characterize further the effect of Ca²⁺ on PKC-potentiated responses, we engineered the mutations N598R (for N1-lacking receptors) and N619R (for N1-containing receptors) in the M2 (channel lining or P) region of each of the three NR1 splice variants (Fig. 6A). Introduction of an Arg in place of N598 greatly reduces Ca²⁺ permeability of recombinant NMDA receptors (Burnashev et al., 1992; Kawajiri and Dingledine, 1993; Sakurada et al., 1993). In Ca²⁺ Ringer's solution, current amplitudes in oocytes expressing the NMDA receptor channel mutant were reduced compared with those of wild-type receptors and lacked the initial peak (Fig. 6B; currents were measured in oocytes from the same batch injected with the same amount of RNA). PKC potentiation of the mutant NR1₀₁₁(N598R) receptors did not differ significantly from that of wild-type NR1₀₁₁ receptors (2.6 ± 0.4- vs 3.1 ± 0.2-fold in Ca²⁺ Ringer's solution; Fig. 6C, wild-type data from Fig. 1B). However, PKC potentiation of NR1₁₁₁(N619R) receptors was markedly reduced relative to that of the corresponding wild-type receptor (3.2 ± 0.4- vs 6.2 ± 0.4-fold). PKC potentiation of NR1₁₀₀(N619R) receptors was also reduced relative to that of the corresponding wild-type receptor (5.1 ± 0.5- vs 12.2 ± 0.8-fold). In all three cases, PKC potentiation of the mutant NMDA receptor measured in Ca²⁺ Ringer's solution was similar to that of the corresponding wild-type receptor measured in Ba²⁺ Ringer's solution (Fig. 6C). Thus, the M2 channel mutation abolished the Ca²⁺ amplification.

---

Fig. 6. Mutant NMDA receptors with reduced Ca²⁺ permeability do not exhibit Ca²⁺ amplification. A, Schematic of the NR1 receptor subunit with the amino acid sequence of the channel-lining domain (M2). The substitution N598R in NR1₀₁₁ (and N619R for the N1-containing receptors) greatly reduces their Ca²⁺ permeability. B, Responses of Xenopus oocytes injected with NR1₀₁₁(N598R), NR1₁₁₁(N619R), and NR1₁₀₀(N619R) RNA. Currents were elicited by bath application of NMDA (300 µM with 10 µM glycine) in Ca²⁺ Ringer's solution before (left) and after (right) incubation with TPA. Responses of mutant receptors were reduced in amplitude, relative to those of the corresponding wild-type receptors, and lacked the initial peak observed in Ca²⁺ Ringer's solution. C, PKC potentiation of responses of the three mutant receptors. PKC potentiated NR1₀₁₁(N598R), NR1₁₁₁(N619R), and NR1₁₀₀(N619R) receptors to 2.6 ± 0.4-, 3.2 ± 0.4-, and 5.1 ± 0.5-fold of the control responses, respectively. PKC potentiation of the three mutant receptors measured in Ca²⁺ Ringer's solution did not differ significantly from that of the corresponding wild-type receptor measured in Ba²⁺ Ringer's solution (Ba²⁺ data from Fig. 1B; p > 0.05 for all three comparisons). Similarly, PKC potentiation of NR1₀₁₁(N598R) receptors and NR1₁₁₁(N619R) receptors did not differ significantly (p > 0.05). PKC potentiation of NR1₁₀₀(N619R) receptors was significantly greater than potentiation of the other two mutant receptors (p < 0.05).
[View Larger Version of this Image (29K GIF file)]

---

PKC potentiation and Ca²⁺ amplification are independent of agonist concentration

To investigate further whether PKC potentiation and Ca²⁺ amplification are reduced under conditions of reduced Ca²⁺ influx, we compared PKC potentiation of NR1₀₁₁ and NR1₁₀₀ receptors at 5 and 300 µM NMDA (with 10 µM glycine). For NR1₀₁₁ receptors, the current amplitude at 5 µM NMDA was 55 ± 8% of that at 300 µM NMDA; for NR1₁₀₀ receptors, the current amplitude at 5 µM NMDA was 19 ± 4% of that at 300 µM NMDA. The degree of PKC potentiation, however, was similar at the two agonist concentrations (4.4 ± 0.4 at 5 µM NMDA vs 3.7 ± 0.3 at 300 µM NMDA for NR1₀₁₁ receptors; 9.8 ± 1.9 at 5 µM NMDA vs 8.7 ± 0.4 at 300 µM NMDA for NR1₁₀₀ receptors) (Fig. 7). The finding that PKC potentiation is unchanged at low agonist concentration suggests that Ca²⁺ amplification is the same at low and high mean current levels per channel. It follows that Ca²⁺ amplification requires neither spatial summation of Ca²⁺ influx from neighboring channels nor temporal summation of Ca²⁺ influx from successive periods when the receptor is fully occupied by agonists during NMDA and glycine application. (Temporal summation might occur between successive openings in a burst.) Ca²⁺ inactivation of NMDA receptors also occurs at low agonist concentration (Legendre et al., 1993) and thus also appears not to require summation of Ca²⁺ influx from successive binding events or neighboring channels.

---

Fig. 7. PKC potentiation does not vary with agonist concentration. Responses of NR1₀₁₁ and NR1₁₀₀ receptors elicited by 5 µM or 300 µM NMDA with 10 µM glycine were recorded in 1 mM Ca²⁺ Ringer's solution before and after TPA application. For both receptors, TPA potentiation of responses elicited by 5 µM NMDA (open bars) did not differ significantly from potentiation of responses elicited by 300 µM NMDA (cross-hatched bars; p > 0.05). For NR1₀₁₁ receptors, control responses at 5 µM NMDA were reduced to 55 ± 8% of control responses at 300 µM NMDA and for NR1₁₀₀ receptors to 19 ± 4% of control responses at 300 µM NMDA.
[View Larger Version of this Image (27K GIF file)]

---

Neutralization of positively charged residues within the N1 splice cassette reduces PKC potentiation of NMDA receptors

The N1 splice cassette alters agonist affinity, current amplitude, spermine and Zn²⁺ potentiation, and proton inhibition of recombinant NMDA receptors (Durand et al., 1992, 1993; Hollmann et al., 1993; Zhang et al., 1994; Zheng et al., 1994; Traynelis et al., 1995), and many of these effects are reversed by neutralization of positive charges in N1. To determine whether the greater PKC potentiation observed for splice variants containing the N1 cassette is affected by the presence of the six positively charged residues, we substituted the neutral amino acid alanine for each of three positively charged residues at either end of the N1 splice cassette (N1-1 and N1-2) or for all six positively charged residues (N1-3; Fig. 8A). The three mutant receptors exhibited reduced current amplitudes relative to that of the wild-type NR1₁₁₁ receptor (data not illustrated). In Ca²⁺ Ringer's solution, PKC potentiation of N1-1, N1-2, and N1-3 receptors was reduced markedly relative to that of wild-type NR1₁₁₁ receptors (to 3.5 ± 0.4-, 2.9 ± 0.3-, and 4.1 ± 0.5-fold of control responses, respectively) and was similar to potentiation of wild-type NR1₀₁₁ receptors (3.1 ± 0.2-fold; Fig. 8B). Because neutralization of the positive charges in the N1 insert reduces current amplitude (defined as the NMDA response obtained after injection of a constant amount of RNA) (Hollmann et al., 1993; Zheng et al., 1994), reduction in Ca²⁺ influx could account for the observed decrease in PKC potentiation.

---

Fig. 8. Neutralization of positive charges within N1 Reduces Ca²⁺ amplification. A, NR1 receptor subunit with predicted membrane domains and N1 cassette sequence alignment for the wild-type NR1₁₁₁ receptor and the three mutant receptors, N1-1, N1-2, and N1-3. Substitutions of alanine for positively charged amino acids within the N1 insert are indicated in bold. B, PKC potentiation of wild-type NR1₀₁₁, mutant N1-1, N1-2, and N1-3, and wild-type NR1₁₁₁ receptors. Experiments were performed in Ca²⁺ Ringer's solution. PKC potentiated responses of NR1₁₁₁(N1-1), NR1₁₁₁(N1-2), and NR1₁₁₁(N1-3) receptors to 3.5 ± 0.4-, 2.9 ± 0.3-, and 4.1 ± 0.5-fold of control responses. These values were similar to those for wild-type NR1₀₁₁ receptors (3.1 ± 0.2; Fig. 1B; p > 0.05 for N1-1 and N1-2; p < 0.05 for N1-3) and significantly less than the value for wild-type NR1₁₁₁ receptors (6.0 ± 0.4; p < 0.005).
[View Larger Version of this Image (34K GIF file)]

---

---

DISCUSSION

PKC potentiation of recombinant NMDA receptors is amplified by Ca²⁺ influx

In the present study, alternative splicing and extracellular Ca²⁺ were shown to affect PKC potentiation of recombinant NR1 receptors expressed in Xenopus oocytes. For N1-containing receptors, PKC potentiation was greater when measured in Ca²⁺ Ringer's solution than when measured in Ba²⁺ Ringer's solution. The data are consistent with a mechanism in which Ca²⁺ entering through the activated receptor binds to the channel or a closely associated molecule to increase channel opening; this amplification would be greater after PKC action. Contamination by Ca²⁺-activated Cl currents was minimal as discussed below. Ca²⁺ was effective when present during the application of NMDA and had no effect during activation of PKC by TPA. The evidence that the amplification requires a rise in intracellular Ca²⁺ is the following: (1) amplification is increased by increasing extracellular Ca²⁺ (Fig. 2); (2) amplification is reduced by depolarizing to reduce the driving force for Ca²⁺ (Fig. 3); (3) amplification is reduced in mutant receptors with reduced Ca²⁺ permeability (Fig. 6); and (4) amplification is prevented by applying a membrane-permeant form of the Ca²⁺ chelator BAPTA (Fig. 5). In addition, the splice variants containing the N1 cassette exhibit greater Ca²⁺ amplification (Fig. 1), possibly because they generate larger currents, which could be associated with greater Ca²⁺ influx. The reduced amplification observed after neutralization of positive charges in the N1 cassette (Fig. 8) is consistent with this interpretation, because these mutations reduce current amplitude. Furthermore, the N1-lacking receptor, NR1₀₁₁, which has a smaller current amplitude, exhibited Ca²⁺ amplification at increased extracellular Ca²⁺; thus, the N1 cassette is not required for Ca²⁺ amplification.

The degree of Ca²⁺ amplification was evaluated by comparison with responses in Ba²⁺. Ba²⁺ is unlikely to have any amplifying effect, because potentiation in Ba²⁺ was similar to that in Ca²⁺ after BAPTA (Fig. 5) and to that of the mutant receptor with reduced Ca²⁺ permeability (Fig. 6). In the simplest model, PKC does not affect the Ca²⁺ amplification directly but increases channel open time and/or conductance, thereby increasing Ca²⁺ influx and the amount of amplification. PKC may also increase sensitivity of the receptor to intracellular Ca²⁺. Alternatively, PKC action may increase single-channel conductance by reducing divalent ion binding in the channel (as has been suggested for PKC action on Mg²⁺ block of NMDA receptors in trigeminal neurons; Chen and Huang, 1992); if Ca²⁺ ions were affected more than Ba²⁺ ions, it could account for the greater potentiation in Ca²⁺. Because BAPTA blocks the Ca²⁺ amplification after PKC, it is unlikely that PKC increases channel conductance. Another possibility might be that PKC increases the plateau response by reducing Ca²⁺-dependent inactivation. This mechanism is unlikely, because the action of BAPTA indicates that there is little Ca²⁺-dependent inactivation either before or after TPA application. (Moreover, the inactivation would have to be rapid enough to be undetected in the rising phase of the response to bath applied agonists.) A final possibility to be considered is that Ca²⁺ causes insertion of new receptor molecules. This mechanism also appears unlikely because of the rapid onset and reversibility of the Ca²⁺ amplification (Fig. 4).

Ca²⁺ amplification is not an artifact of Ca²⁺-activated chloride current

A number of observations indicate that I_Cl(Ca) does not contribute significantly to PKC potentiation or Ca²⁺ amplification, as measured in this study. (1) The chloride channel blocker, niflumic acid, had only a small effect on the amplitude of the plateau responses and did not reduce PKC potentiation measured in 1 mM Ca²⁺ Ringer's solution at 60 mV (Fig. 3A). Leonard and Kelso (1990) reported a greater effect of niflumic acid on NMDA responses in oocytes expressing rat brain mRNA, but this difference may have resulted from use of brain mRNA, which may encode additional Ca²⁺-activated Cl channels and from recording at 80 mV in 2 mM external Ca²⁺, which would increase I_Cl(Ca). (2) Ca²⁺ amplification is present at 20 mV, a value near E_Cl in oocytes (Fig. 3B,C). At this holding potential, the chloride current is small, but Ca²⁺ amplification persists, although reduced, presumably because of the reduced driving force for Ca²⁺ influx. (3) We measure in oocytes a reversal potential for recombinant NMDA receptors of about 5 mV (data not illustrated; also see Hollmann et al., 1993). This value is close to that reported for neuronal NMDA receptors (cf. Mayer and Westbrook, 1987), which indicates that there is little I_Cl(Ca) contribution. (4) The degree of Ca²⁺ amplification was not changed when Ca²⁺ influx was reduced by reducing agonist concentration (Fig. 7). Also, the degree of Ca²⁺ amplification was the same for oocytes generating large and small currents in response to saturating NMDA, reflecting differences in the level of receptor expression (data not illustrated). I_(Ca)Cl would be expected to decrease with decrease in NMDA elicited currents.

Are Ca²⁺ influx and Ca²⁺ amplification during NMDA application regenerative?

The mechanism of the proposed Ca²⁺ amplification is as yet unknown, but single-channel studies and mutational analysis will undoubtedly further elucidate the molecular basis. Ca²⁺ may act directly on the channel protein or on a closely associated accessory protein expressed by the Xenopus oocyte. Candidate proteins are calmodulin and Ca²⁺- and calmodulin-dependent kinases, implicated in NMDA-dependent LTP. The rapid rise in current amplitude on transfer of the oocyte from Ba²⁺ to Ca²⁺ Ringer's solution and rapid decay on transfer from Ca²⁺ to Ba²⁺ Ringer's solution argues against a covalent modification, such as phosphorylation or dephosphorylation and in favor of a direct action of Ca²⁺ (or Ca²⁺-calmodulin complex) on the cytoplasmic face of the receptor. Ca²⁺-calmodulin binds to a site in the C1 cassette and a site in C0, the region between TM4 and C1 of the NR1 subunit. However, binding to these sites decreases channel open time in heteromeric receptors with NR2A expressed in HEK 293 cells (Ehlers et al., 1996).

The Ca²⁺ amplification should tend to be regenerative. However, in our experiments the amplification was independent of agonist concentration (Fig. 7). This finding, together with our observation that Ca²⁺ amplification is independent of the level of receptor expression (data not shown), suggests that there was neither spatial summation of Ca²⁺ influx from neighboring channels nor temporal summation of Ca²⁺ influx from successive bursts of openings caused by periods of full occupancy of the receptor by NMDA and glycine. It follows that under these conditions there was no regenerative response.

As noted above, neuronal receptors can show Ca²⁺-dependent inactivation (Legendre et al., 1993; Rosenmund et al., 1995). In recombinant receptors expressed in HEK 293 cells, Ca²⁺-dependent inactivation is affected by the NR2 subunit, being greatest in NR1/NR2A receptors, less in NR1/NR2B receptors, and virtually absent in NR1/NR2C receptors (Krupp et al., 1996). In Xenopus oocytes, increase in extracellular Ca²⁺ was reported to increase NMDA response amplitude comparable to the Ca²⁺ amplification proposed here; however, unlike the results in Figure 2, the response amplitude was not reduced at higher concentrations of Ca²⁺ (Koltchine et al., 1996).

Recombinant NMDA receptors expressed in Xenopus oocytes exhibit a late, slowly rising phase in NMDA responses, particularly evident in N1-containing NR1 receptors, in the presence or absence of activators of PKC (Figs. 1A, 5) (Koltchine et al., 1996). This slow, Ca²⁺-dependent response is more likely to occur at higher agonist concentrations and after PKC potentiation. It may represent the release of Ca²⁺ from intracellular pools, although the persistence of the response in BAPTA argues against this mechanism.

Does PKC potentiation involve phosphorylation of the NR1 protein?

PKC phosphorylates specific serine residues in the NR1₀₁₁ receptor expressed transiently in HEK 293 cells (Tingley et al., 1993). The four identified series are contained in the C1 cassette, although our electrophysiological findings indicate that splicing out the C1 and C2 cassettes increases PKC potentiation (Fig. 1) (Durand et al., 1992, 1993). Thus, PKC potentiation may not require phosphorylation of the receptor itself, and phosphorylation of C1 may even reduce PKC potentiation. In agreement, mutation of the phosphorylatable serines to alanines increases TPA potentiation (Zhang et al., 1996). It is then reasonable to suggest that there is another molecule associated with NR1, phosphorylation of which is responsible for the potentiation. An obvious possibility is NR2A and/or B, which apparently are phosphorylated by PKC (Hall and Soderling, 1997; Leonard and Hell, 1997)

Functional significance of the Ca²⁺ amplification

Although our experiments were performed on recombinant NMDA receptors expressed in Xenopus oocytes, Ca²⁺ amplification is likely to occur after PKC potentiation of neuronal NMDA receptors. As noted above, PKC potentiates NMDA receptors in neurons from hippocampus (Aniksztejn et al., 1992), trigeminal nucleus (Chen and Huang, 1992), and spinal cord (Gerber et al., 1989). In our study, extracellular Ca²⁺ and alternative splicing were shown to affect PKC potentiation. These results together with the finding that expression of NR1 splice variants is temporally and spatially regulated (Laurie and Seeburg, 1994; Zukin and Bennett, 1995; Paupard et al., 1997) provide a mechanism whereby NMDA signals can be amplified in specific neuronal populations at times of enhanced synaptic activity. Thus, PKC potentiation of NMDA responses may have a significant impact on cellular events including induction of long-term potentiation and synaptogenesis. Ca²⁺ amplification, if present in neurons, may have particularly important actions in small structures such as dendritic spines, where influxes through neighboring receptor channels would be more likely to interact.

---

FOOTNOTES

Received June 4, 1997; revised Aug. 18, 1997; accepted Aug 26, 1997.

  

This work was supported by National Institutes of Health Grants NS 20752 (R.S.Z.) and NS 07412 (M.V.L.B.). M.V.L.B. is the Sylvia and Robert S. Olnick Professor of Neuroscience. We thank J. Zavilowitz for technical assistance. We are grateful to Drs. S. Nakanishi, V. R. Anantharam, and M. Mishina for providing the NR1₀₁₁, NR1₁₁₁, and mouse -1 (equivalent to rat NR2A) cDNAs, respectively. We thank Dr. T. Opitz and R. Araneda for helpful comments on this manuscript.

Correspondence should be addressed to Dr. R. Suzanne Zukin, Department of Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. 

---

REFERENCES

• Aniksztejn L, Bregestovski P, Ben-Ari Y (1991) Selective activation of quisqualate metabotropic receptor potentiates NMDA but not AMPA responses. Eur J Pharmacol 205:327-328[ISI][Medline].
• Aniksztejn L, Otani S, Ben-Ari Y (1992) Quisqualate metabotropic receptors modulate NMDA currents and facilitate induction of long-term potentiation through protein kinase C. Eur J Neurosci 4:500-505[ISI][Medline].
• Behe P, Stern P, Wyllie DJ, Nassar M, Schoepfer R, Colquhoun D (1995) Determination of NMDA NR1 subunit copy number in recombinant NMDA receptors. Proc R Soc Lond [Biol] 262:205-213[Medline].
• Blahos II J, Wenthold RJ (1996) Relationship between N-methyl-D-aspartate receptor NR1 splice variants and NR2 subunits. J Biol Chem 271:15669-15674[Abstract/Free Full Text].
• Bliss TVP, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39[Medline].
• Buller AL, White MM (1990) Functional acetylcholine receptors expressed in Xenopus oocytes after injection of Torpedo beta, gamma, and delta subunit RNAs are a consequence of endogenous oocyte gene expression. Mol Pharmacol 37:423-428[Abstract].
• Burnashev N, Schoepfer R, Monyer H, Ruppersberg JP, Gunther W, Seeburg PH, Sakmann B (1992) Control by asparagine residues of calcium permeability and magnesium blockade in the NMDA receptor. Science 257:1415-1419[Abstract/Free Full Text].
• Chen L, Huang LYM (1991) Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a µ opioid. Neuron 7:319-326[ISI][Medline].
• Chen L, Huang LYM (1992) Protein kinase C reduces Mg²⁺ block of NMDA-receptor channels as mechanism of modulation. Nature 356:521-523[Medline].
• Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13:171-182[ISI][Medline].
• Constantine-Paton M (1990) NMDA receptor as a mediator of activity-dependent synaptogenesis in the developing brain. Cold Spring Harbor Symp Quant Biol 55:431-443[Medline].
• Durand GM, Gregor P, Zheng X, Bennett MVL, Uhl GR, Zukin RS (1992) Cloning of an apparent splice variant of the rat N-methyl-D-aspartate receptor NMDAR1 with altered sensitivity to polyamines and activators of protein kinase C. Proc Natl Acad Sci USA 89:9359-9363[Abstract/Free Full Text].
• Durand GM, Bennett MVL, Zukin RS (1993) Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by polyamines and protein kinase C. Proc Natl Acad Sci USA 90:6731-6735[Abstract/Free Full Text].
• Ehlers MD, Tingley WG, Huganir RL (1995) Regulated subcellular distribution of the NR1 subunit of the NMDA receptor. Science 269:1734-1737[Abstract/Free Full Text].
• Ehlers MD, Zhang S, Bernhardt JP, Huganir RL (1996) Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell 84:745-755[ISI][Medline].
• Gerber G, Kangrga I, Ryu PD, Larew JSA, Randic M (1989) Multiple effects of phorbol esters in the rat spinal dorsal horn. J Neurosci 9:3606-3617[Abstract].
• Hall RA, Soderling TR (1997) Differential surface expression and phosphorylation of the N-methyl-D-aspartate receptor subunits NR1 and NR2 in cultured hippocampal neurons. J Biol Chem 272:4135-4140[Abstract/Free Full Text].
• Hedin KE, Lim NF, Clapham DE (1996) Cloning of a Xenopus laevis inwardly rectifying K⁺ channel subunit that permits GIRK1 expression of I_KACh currents in oocytes. Neuron 16:423-429[ISI][Medline].
• Hollmann M, Boulter J, Maron C, Beasley L, Sullivan J, Pecht G, Heinemann S (1993) Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron 10:943-954[ISI][Medline].
• Jahr CE, Stevens CF (1993) Calcium permeability of the N-methyl-D-aspartate receptor channel in hippocampal neurons in culture. Proc Natl Acad Sci USA 90:11573-11577[Abstract/Free Full Text].
• Kawajiri S, Dingledine R (1993) Multiple structure determinants of voltage-dependent magnesium block in recombinant NMDA receptors. Neuropharmacology 32:1203-1211[ISI][Medline].
• Kelso SR, Nelson TE, Leonard JP (1992) Protein kinase C-mediated enhancement of NMDA currents by metabotropic glutamate receptors in Xenopus oocytes. J Physiol (Lond) 449:705-718[Abstract/Free Full Text].
• Koltchine VV, Anantharam V, Bayley H, Treistman SN (1996) Alternative splicing of the NMDAR1 subunit affects modulation by calcium. Mol Brain Res 39:99-108[Medline].
• Krupp J, Vissel B, Heinemann S, Westbrook GL (1996) Molecular determinants of Ca-dependent inactivation in recombinant NMDA receptors. Soc Neurosci Abstr 22:589.
• Kushner L, Lerma J, Zukin RS, Bennett MVL (1988) Coexpression of N-methyl-D-aspartate and phencyclidine receptors in Xenopus oocytes injected with rat brain mRNA. Proc Natl Acad Sci USA 85:3250-3254[Abstract/Free Full Text].
• Kushner L, Lerma J, Bennett MVL, Zukin RS (1989) Using the Xenopus oocyte system for expression and cloning of neuroreceptors and channels. In: Methods of neuroscience (Conn PM, ed), pp 3-28. Orlando: Academic.
• Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki, Kumanishi T, Arakawa M, Mishina M (1992) Molecular diversity of the NMDA receptor channel. Nature 358:36-41[Medline].
• Laurie DJ, Seeburg PH (1994) Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. J Neurosci 14:3180-3194[Abstract].
• Legendre P, Rosenmund C, Westbrook GL (1993) Inactivation of NMDA channels in cultured hippocampal neurons by intracellular calcium. J Neurosci 13:674-684[Abstract].
• Leonard AS, Hell JW (1997) Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J Biol Chem 272:12107-12115[Abstract/Free Full Text].
• Leonard JP, Kelso SR (1990) Apparent desensitization of NMDA responses in Xenopus oocytes involves calcium-dependent chloride current. Neuron 4:53-60[ISI][Medline].
• Markram H, Segal M (1990) Acetylcholine potentiates responses to N-methyl-D-aspartate in the rat hippocampus. Neurosci Lett 113:62-65[ISI][Medline].
• Mayer ML, Westbrook GL (1987) Permeation and block of N-methyl-D-aspartic acid channels by divalent cations in mouse cultured central neurons. J Physiol (Lond) 394:501-527[Abstract/Free Full Text].
• Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357:70-74[Medline].
• Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217-1221[Abstract/Free Full Text].
• Mori H, Mishina M (1995) Structure